Login / Signup

Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.

Alessandro RizzoVeronica MollicaSara MerlerFranco MorelliGiulia SorgentoniMarco OderdaMatteo SantoniFrancesco Massari
Published in: Expert opinion on drug metabolism & toxicology (2022)
Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • dna damage
  • peritoneal dialysis
  • risk factors
  • prognostic factors
  • risk assessment
  • combination therapy
  • current status